Shoba Alaska (Reddy-Holdcraft) Navai MD
Assistant Professor of Pediatrics, Baylor College of Medicine
Join to View Full Profile
6701 Fannin St.Suite 1400Houston, TX 77030
Phone+1 832-822-4242
Dr. Navai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Shoba (Reddy-Holdcraft) Navai is an Assistant Professor and specialist in Pediatric Hematology & Oncology located in Houston, TX. She completed her medical education in 2010 at the Medical College of Georgia at Augusta University and pursued her residency and fellowship at Baylor College of Medicine, where she has been employed since 2017. Her expertise includes immunotherapy and pediatric solid tumor oncology. Dr. Navai has contributed to publications on topics such as rare pediatric cancers and the effects of immune therapies and leads various clinical trials, including studies on HER2-specific CAR T cells for pediatric conditions.
Education & Training
Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2014 - 2017- Baylor College of Medicine (Houston)Residency, Pediatrics, 2010 - 2014
Medical College of Georgia at Augusta UniversityClass of 2010
Certifications & Licensure
TX State Medical License 2012 - 2026
American Board of Pediatrics Pediatrics- American Board of Pediatrics Pediatric Hematology-Oncology
Clinical Trials
- VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors Start of enrollment: 2023 Apr 18
Roles: Principal Investigator, Contact
- HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma Start of enrollment: 2021 Dec 07
- T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors Start of enrollment: 2016 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors.Matthew E Campbell, Sonja Stutzman, Sharon Primeaux, Deseray Sida, Minjae Lee
Pediatric Blood & Cancer. 2025-09-12 - Cardiovascular Complications of Immune Effector Cell Therapies in Pediatric Hematological and Solid Tumors.Aaron B Ross, Kriti Puri, Thomas L Johnson, Lilliam D Correa, Tami D John
Pediatric Blood & Cancer. 2025-04-01 - A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function.Daniel Landi, Shoba A Navai, Rebecca M Brock, Kristen Fousek, Zeid Nawas
Cancer Research Communications. 2025-03-01
Press Mentions
The Faris Foundation Grant Funds Research for Advanced Sarcoma Clinical TrialDecember 4th, 2020
CAR T-cell Therapy for Mesothelioma Proving Effective in Clinical TrialApril 11th, 2019
Immune System Therapy Shows Wider Promise Against CancerApril 1st, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
